Close Menu

malaria

The research will seek to discover the genetic causes for the malaria parasite's ability to develop drug resistance.

By looking for signals of natural selection in Plasmodium falciparum and performing a genome-wide association study of resistance, an international research team has identified genes suspected of contributing to resistance in the malaria parasite.

Researchers from the US and Peru have demonstrated the feasibility of re-sequencing the Plasmodium vivax malaria parasite directly from the blood of infected patients.

Scientists from the US Centers for Disease Control determined that a so-called "nested" PCR assay is more effective than easier-to-perform semi-nested or single-tube multiplex PCR assays for detecting Plasmodium, the parasite that causes malaria.

A University of York team used transcriptome sequencing and pedigree studies to create a genetic map for Artemisia annua, a plant that contains a compound used to help treat some forms of malaria.

The HIV center, located in a New York City suburb, will allow Profectus in December to accommodate more than 20 new researchers it plans to hire over the next two years, in addition to the 13 now based in temporary space.

The Swiss foundation has become a member of the CPGR in order to develop point-of-care tests for African diseases.

Nearly $14 million next year will support centers to study malaria and develop gene-based diagnostics.

Although the developers note that the protocol particularly benefits the sequencing of AT-rich genomes, they say that it is also quicker than the standard method, which requires PCR amplification, and "should be used routinely to prepare libraries for Genome Analyzer sequencing."

Pages

Researchers are developing a breath test to determine how severe patients' methylmalonic acidemia disease is, FierceBiotech reports.

NPR reports that vaccine developers are working on SARS-CoV-2 vaccines that are easier to store or administer than the current crop.

Reuters reports that France is to recommend that people under 55 who received one dose of AstraZeneca's SARS-CoV-2 vaccine receive a different vaccine for their second dose.